TNFRSF10B and neoplasm: With the exception of the TRAIL–Melittin conjugate, whose gain of function was rather limited, these findings suggest that conjugation of DR4 or DR5 derivatives in an ADC-like antitumoral drug could also lead in the future to efficient TRAIL therapies, provided that such a compound remains safe in vivo, but efficient in inhibiting tumor growth.